These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7988268)

  • 1. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
    Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
    Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
    Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 immunostaining is correlated with reduced survival and is not correlated with gene mutations in resected pulmonary large cell carcinomas.
    Massoni Neto LM; Bianchi CP; Ab'Saber AM; Parra ER; Takagaki T; Pereira JC; Soares FA; Leite K; Capelozzi VL
    Braz J Med Biol Res; 2007 Aug; 40(8):1045-53. PubMed ID: 17665040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
    Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
    Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
    J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
    Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
    Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [P53 and P16 gene mutations in non-small cell lung cancer].
    Jassem E; Ramlau R; Dziadziuszko R; Szymanowska A; Jakóbkiewicz J; Lamperska K; Kobierska G; Skokowski J; Dyszkiewicz W; Mackiewicz A; Zylicz M; Jassem J
    Pneumonol Alergol Pol; 2002; 70(1-2):64-70. PubMed ID: 12148179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
    Mitsudomi T; Hamajima N; Ogawa M; Takahashi T
    Clin Cancer Res; 2000 Oct; 6(10):4055-63. PubMed ID: 11051256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival.
    Mitsudomi T; Oyama T; Nishida K; Ogami A; Osaki T; Nakanishi R; Sugio K; Yasumoto K; Sugimachi K
    Ann Oncol; 1995; 6 Suppl 3():S9-13. PubMed ID: 8616120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.